Fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation

Department of Medicine, Division of Hematology, Keio University School of Medicine, Tokyo, Japan.
Transplant Infectious Disease (Impact Factor: 1.98). 04/2011; 14(1):91-4. DOI: 10.1111/j.1399-3062.2011.00647.x
Source: PubMed

ABSTRACT Rhodotorula species have been increasingly recognized as emerging pathogens, particularly in immunocompromised patients. We herein report on a patient with myelodysplastic syndrome who developed fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor. He developed severe acute graft-versus-host disease requiring high-dose steroids, and had serially been administered fluconazole and micafungin for the prophylaxis of fungal infection. Although several cases of Rhodotorula infection after HSCT have been reported, all of them were recipients of autologous HSCT, not allogeneic HSCT. A review of all the reported cases of Rhodotorula infection after HSCT revealed that all patients had received fluconazole or echinocandins before the onset of infection. The findings suggest that Rhodotorula species could be causative yeasts, particularly in patients receiving fluconazole or echinocandins, both of which are inactive against the species.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rhodotorula is an emerging opportunistic fungal pathogen that is rarely reported to cause endocarditis. We describe a case involving a patient who developed endocarditis due to Rhodotorula mucilaginosa and Staphylococcus epidermidis, proven by culture and histopathology. The case illustrates the unique diagnostic and therapeutic challenges relevant to Rhodotorula spp.
    Journal of clinical microbiology 11/2013; DOI:10.1128/JCM.01950-13 · 4.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections have emerged as a major cause of increased morbidity and mortality among severely immunosuppressed patients with haematological malignancy. Micafungin, a new member of the echinocandin class, is a valuable addition to the antifungal armamentarium of the 21st century as it is active against Candida species, Aspergillus species, and other unusual mycoses that frequently affect these high risk patients. Available data on the safety and efficacy of micafungin as prophylaxis, preemptive/empirical treatment, or treatment of documented invasive fungal infection in patients with haematological malignancies are summarized in this review.
    Mycoses 04/2012; 55(s1). DOI:10.1111/j.1439-0507.2011.02113.x · 1.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This ESCMID and ECMM Joint Clinical Guidelines focus on the diagnosis and management of mucormycosis. Only a few of the numerous recommendations can be summarised here. To diagnose mucormycosis, direct microscopy preferably using optical brighteners, histopathology and culture are strongly recommended. Pathogen identification to species level by molecular methods and susceptibility testing are strongly recommended to establish epidemiological knowledge. The recommendation for guiding treatment based on minimal inhibitory concentrations is supported only marginally. Imaging is strongly recommended to determine the extent of disease. To differentiate mucormycosis from aspergillosis in haematological malignancy and stem cell transplantation recipients, identification of the reversed halo sign on computed tomography is advised with moderate strength. For adults and children we strongly recommend surgical debridement in addition to immediate first-line antifungal treatment with liposomal or lipid-complex amphotericin B with a minimum dose of 5 mg/kg/d. Amphotericin B deoxycholate is better avoided due to severe side effects. For salvage treatment we strongly recommend posaconazole 4x200 mg/d. Reversal of predisposing conditions is strongly recommended, i.e. using granulocyte colony stimulating factor in haematologic patients with ongoing neutropaenia, controlling hyperglycaemia and ketoacidosis in diabetic patients, and limiting glucocorticosteroids to the minimum dose required. We recommend against using deferasirox in haematological patients outside of clinical trials, and marginally support a recommendation for deferasirox in diabetic patients. Hyperbaric oxygen is supported with marginal strength only. Finally, we strongly recommend continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors. This article is protected by copyright. All rights reserved.
    Clinical Microbiology and Infection 01/2014; DOI:10.1111/1469-0691.12371 · 4.58 Impact Factor


Available from